Síndrome clínico aislado: diagnóstico y riesgo de desarrollar esclerosis múltiple clínicamente definida / Clinically isolated syndrome: diagnosis and risk of developing clinically definite multiple sclerosis

Introducción: La mayoría de los pacientes con esclerosis múltiple (EM) debutan con un síndrome clínico aislado (SCA). Es importante diferenciar este SCA de otras patologías neurológicas agudas o subagudas y estimar el riesgo de desarrollar una esclerosis múltiple clínicamente definida (EMCD), pues un segundo ataque clínico en un corto período de tiempo se asocia con peor pronóstico a largo plazo. Desarrollo: Se realizó una revisión bibliográfica con el objetivo de contrastar diferentes variables, tales como la resonancia magnética (RM) y distintos marcadores biofluídicos como las bandas oligoclonales IgG (BOC), bandas oligoclonales IgM (BOCM), bandas oligoclonales IgM lípido específicas (BOCM-LE), índice de cadenas ligeras libres Kappa (κ index) mediante la determinación de las cadenas ligeras libres kappa en líquido cefalorraquídeo (LCR), neurofilamentos de cadenas ligeras en LCR (NfLL) y suero (NfLS) y la proteína chitinasa 3-like 1 (CHI3L1) en LCR (CHI3L1L) y suero (CHI3L1S), con el objetivo de mejorar la precisión diagnóstica y predecir los riesgos de un segundo ataque clínico tras un SCA. Conclusión: Unas BOC positivas junto con la identificación de lesiones por RM, reducirán el tiempo de diagnóstico y nos indicarán que la mayoría de los pacientes con SCA evolucionarán a EM. Un κ index > 10,6 y una concentración de NfLL > 1.150 ng/L, nos muestran que los SCA tienen más probabilidades de convertirse en EM durante el primer año (40/50%). El 90% de los pacientes con SCA y niveles de CHI3L1S > 33 ng/mL, y el 100% con presencia BOCM-LE se transforman en EM durante el primer año.(AU)

Introduction: In most cases, multiple sclerosis (MS) initially presents as clinically isolated syndrome (CIS). Differentiating CIS from other acute or subacute neurological diseases and estimating the risk of progression to clinically definite MS is essential since presenting a second episode in a short time is associated with poorer long-term prognosis. Development: We conducted a literature review to evaluate the usefulness of different variables in improving diagnostic accuracy and predicting progression from CIS to MS, including magnetic resonance imaging (MRI) and such biofluid markers as oligoclonal IgG and IgM bands, lipid-specific oligoclonal IgM bands in the CSF, CSF kappa free light-chain (KFLC) index, neurofilament light chain (NfL) in the CSF and serum, and chitinase 3–like protein 1 (CHI3L1) in the CSF and serum. Conclusions: Codetection of oligoclonal IgG bands and MRI lesions reduces diagnostic delays and suggests a high risk of CIS progression to MS. A KFLC index > 10.6 and CSF NfL concentrations > 1150 ng/L indicate that CIS is more likely to progress to MS within one year (40-50%); 90% of patients with CIS and serum CHI3L1 levels > 33 ng/mL and 100% of those with lipid-specific oligoclonal IgM bands present MS within one year of CIS onset.

Clinically isolated syndrome: Diagnosis and risk of developing clinically definite multiple sclerosis.

INTRODUCTION: In most cases, multiple sclerosis (MS) initially presents as clinically isolated syndrome (CIS). Differentiating CIS from other acute or subacute neurological diseases and estimating the risk of progression to clinically definite MS is essential since presenting a second episode in a short time is associated with poorer long-term prognosis. DEVELOPMENT: We conducted a literature review to evaluate the usefulness of different variables in improving diagnostic accuracy and predicting progression from CIS to MS, including magnetic resonance imaging (MRI) and such biofluid markers as oligoclonal IgG and IgM bands, lipid-specific oligoclonal IgM bands in the CSF, CSF kappa free light-chain (KFLC) index, neurofilament light chain (NfL) in the CSF and serum, and chitinase 3-like protein 1 (CHI3L1) in the CSF and serum. CONCLUSIONS: Codetection of oligoclonal IgG bands and MRI lesions reduces diagnostic delays and suggests a high risk of CIS progression to MS. A KFLC index > 10.6 and CSF NfL concentrations > 1150 ng/L indicate that CIS is more likely to progress to MS within one year (40%-50%); 90% of patients with CIS and serum CHI3L1 levels > 33 ng/mL and 100% of those with lipid-specific oligoclonal IgM bands present MS within one year of CIS onset.

Clinically isolated syndrome: diagnosis and risk of developing clinically definite multiple sclerosis. / Síndrome clínico aislado: diagnóstico y riesgo de desarrollar esclerosis múltiple clínicamente definida.

INTRODUCTION: In most cases, multiple sclerosis (MS) initially presents as clinically isolated syndrome (CIS). Differentiating CIS from other acute or subacute neurological diseases and estimating the risk of progression to clinically definite MS is essential since presenting a second episode in a short time is associated with poorer long-term prognosis. DEVELOPMENT: We conducted a literature review to evaluate the usefulness of different variables in improving diagnostic accuracy and predicting progression from CIS to MS, including magnetic resonance imaging (MRI) and such biofluid markers as oligoclonal IgG and IgM bands, lipid-specific oligoclonal IgM bands in the CSF, CSF kappa free light-chain (KFLC) index, neurofilament light chain (NfL) in the CSF and serum, and chitinase 3-like protein 1 (CHI3L1) in the CSF and serum. CONCLUSIONS: Codetection of oligoclonal IgG bands and MRI lesions reduces diagnostic delays and suggests a high risk of CIS progression to MS. A KFLC index > 10.6 and CSF NfL concentrations > 1150 ng/L indicate that CIS is more likely to progress to MS within one year (40-50%); 90% of patients with CIS and serum CHI3L1 levels > 33 ng/mL and 100% of those with lipid-specific oligoclonal IgM bands present MS within one year of CIS onset.

Evaluación de los niveles de NT-proBNP en los derrames pleurales de origen cardíaco / Evaluation of NT-proBNP levels in pleural effusions of cardiac origin

Objetivo: Evaluar el rendimiento diagnóstico del fragmento amino-terminal del péptido natriurético (NT-proBNP) en líquido pleural (LP) y suero (S) en pacientes con insuficiencia cardíaca congestiva (ICC) y valorar su utilidad en la identificación de derrames pleurales (DPs) de origen cardiogénico, frente a los criterios de Light y gradiente de proteínas (PT). Material y métodos: Se analizaron 21 DPs (42,85% trasudados) de los cuales, siete fueron secundarios a ICC. La precisión diagnóstica del NT-proBNP en LP y S y de los criterios de Light se obtuvo mediante el área bajo la curva (AUC). Resultados: NT-proBNP en S presenta mejor rentabilidad diagnóstica (AUC:0,889) que su determinación en LP, criterios de Light y gradiente de PT. Valores por encima de 1.053 pg/ml identifican la etiología cardíaca del derrame con una sensibilidad del 83% y una especificidad del 100%. De los derrames cardiogénicos clasificados erróneamente por el criterio de Light LDH (LP/S), NT-proBNP en S identifica correctamente la totalidad de los derrames (100%). Conclusión: La determinación de NT-proBNP en LP para diferenciar la naturaleza trasudativa de los DPs de origen cardiogénico, no resulta de utilidad en la práctica clínica. En derrames cuya etiología sea dudosa, las concentraciones séricas de NT-proBNP pueden ser útiles para el diagnóstico de ICC

Objective: To evaluate the diagnostic performance of the N-terminal pro-natriuretic peptide (NT-proBNP) in pleural fluid (PF) and serum, in patients with congestive heart failure (CHF) and assess its usefulness in the identification of cardiogenic pleural effusions, against the Light's criteria and protein gradient (PT). Material and Methods: We analyzed 21 DP (42.85% transudates) of which seven were secondary to CHF. The diagnostic accuracy of NT-proBNP in LP and S and the Light's criteria was obtained using the area under the curve (AUC). Results: The serum determination of NT-proBNP presents the best diagnostic yield (AUC: 0.889) than its determination in PF, Light's criteria and protein gradient. Values above 1,053 pg/ml identify the cardiac etiology of the effusion with a sensitivity of 83% and a specificity of 100%. Of the patients misclassified by the Light LDH criteria (LP/S), NT-proBNP in S correctly identifies all of the effusions (100%). Conclusion: The determination of NT-proBNP in pleural fluid to differentiate the transudative nature of cardiogenic pleural effusions, is not useful in clinical practice. In effusions whose etiology is doubtful, seric concentrations of NT-proBNP may be useful for the diagnosis of CHF

Serum cystatin C and microalbuminuria in the detection of vascular and renal damage in early stages.

BACKGROUND: The aim of this study was to assess serum cystatin C and urinary albumin in the early detection of impairment in cardiovascular and renal function. MATERIAL ANS METHODS: Cystatin C was quantified in sera from healthy people, moreover, cystatin C was quantified in a group of patients diagnosed with chronic kidney disease for predicting a measured glomerular filtration rate <60 ml/min/1.73 m2. Finally serum cystatin C and microalbuminuria were measured in patients with increasing of risk of impairment in cardiovascular and renal function (hypertension, diabetes and hyperlipidemia). RESULTS: When the serum cystatin C was quantified in a group of risk, we observe as when being increased the cystatin C, the values of the glomerular filtration rate decreased (p <0.05), the cystatin values C were increased when increasing the age of the patients (p <0.05) and cystatin C values higher than 0.95 mg/l were not observed in patient smaller than 50 years old. In the group of risk, serum cystatin C was high regarding to the values obtained in healthy people in 27.6%, microalbuminuria in the 20.3% and both parameters were high in the 14.4% of patients with a glomerular filtration rate >90 ml/min/1.73 m2, while in patients with a glomerular filtration rate 60-90 ml/min/1.73 m2, cystatin C was high in the 51.7% and the microalbuminuria only in the 6.4%. CONCLUSIONS: Determinations of serum cystatin C associated to the quantification of urinary albumin in patients with cardiovascular risk can optimize the early detection of vascular and renal damage. Cystatin C can show vascular and renal damage in patients without urinary albumin.

Cistatina C sérica y microalbuminuria en la detección del daño vascular y renal en estadios precoces, en pacientes de riesgo sin enfermedad renal crónica / Serum cystatin C and microalbuminuria in the detection of early-stage vascular and renal damage, in at-risk patients without chronic kidney disease

Objetivo: Evaluar la cistatina C sérica y la microalbuminuria en la detección precoz de las alteraciones vasculares y renales. Material y método: La cistatina C sérica fue cuantificada en suero de un grupo de personas sanas y en un grupo de pacientes con enfermedad renal crónica para establecer un valor de cistatina C a partir del cual se pueda predecir un filtrado glomerular <60 ml/min/1.73 m2. Finalmente, la cistatina C sérica y la microalbuminuria fueron cuantificadas en pacientes con un incremento del riesgo de daño vascular y renal (hipertensión, diabetes e hiperlipemia). Resultados: Cuando la cistatina C sérica fue cuantificada en un grupo de riesgo, observamos cómo al aumentar los valores de cistatina C disminuían los valores del filtrado glomerular (p <0,05), que los valores de cistatina C se incrementaban al aumentar la edad de los pacientes (p <0,05) y cómo valores de cistatina C superiores a 0,95 mg/l no se observaron en pacientes con edad inferior a 50 años. En los pacientes del grupo de riesgo con un filtrado glomerular >90 ml/min/1,73 m2, la cistatina C sérica estaba elevada en un 27,6% con respecto a los valores obtenidos en personas sanas; existía microalbuminuria en un 20,3% y elevación de ambos parámetros en un 14,4%. Con valores de filtrado glomerular 60-90 ml/min/1,73 m2, la cistatina C estaba elevada en un 51,7%, la microalbuminuria en un 6,4% y ambos parámetros en un 23,8%. Conclusiones: Determinaciones de cistatina C sérica asociadas a la cuantificación de microalbuminuria en pacientes con riesgo pueden mejorar la detección del daño vascular y renal en estadios precoces. La cistatina C puede poner de manifiesto el daño vascular y renal precoz incluso en pacientes sin microalbuminuria (AU)

Background: The aim of this study was to assess serum cystatin C and urinary albumin in the early detection of impairment in cardiovascular and renal function. Material ans methods: Cystatin C was quantified in sera from healthy people, moreover, cystatin C was quantified in a group of patients diagnosed with chronic kidney disease for predicting a measured glomerular filtration rate <60 ml/min/1.73 m2. Finally serum cystatin C and microalbuminuria were measured in patients with increasing of risk of impairment in cardiovascular and renal function (hypertension, diabetes and hyperlipidemia). Results: When the serum cystatin C was quantified in a group of risk, we observe as when being increased the cystatin C, the values of the glomerular filtration rate decreased (p <0.05), the cistatina values C were increased when increasing the age of the patients (p <0.05) and cystatin C values higher than 0.95 mg/l were not observed in patient smaller than 50 years old. In the group of risk, serum cystatin C was high regarding to the values obtained in healthy people in 27.6%, microalbuminuria in the 20.3% and both parameters were high in the 14.4% of patients with a glomerular filtration rate >90 ml/min/1.73 m2, while in patients with a glomerular filtration rate 60-90 ml/min/1.73 m2, cystatin C was high in the 51.7% and the microalbuminuria only in the 6.4%. Conclusions: Determinations of serum cystatin C associated to the quantification of urinary albumin in patients with cardiovascular risk can optimize the early detection of vascular and renal damage. Cystatin C can show vascular and renal damage in patients without urinary albumin (AU)

[Pharyngitis due to Burkholderia cepacia. Person-to-person transmission]. / Faringitis por Burkholderia cepacia. Transmisión de persona a persona.

Burkholderia cepacia is a Gram-negative bacillus that is widely distributed in nature; it is isolated from the ground, water, plants and vegetables. Generally, it produces nosocomial infection due to contamination of disinfectants, medical equipment, prosthetic material and drugs, such as anesthetics or liquids used in urological irrigation. The most probable mechanism of transmission is through hospital material or through fomites among people after contact for several weeks or months. Recently, it has been considered as an important pathogen in immunocompromised patients, or in those with significant underlying diseases, such as chronic granulomastosis or cystic fibrosis. We present a case of pharyngitis due to B. cepacia and its transmission within a few days in two immunocompetent twin siblings without previous underlying diseases. The infection disappeared after specific treatment for this microorganism was started. We believe that samples should be taken from the pharynx and nasal pits in patients with acute upper respiratory tract processes that do not respond to empiric antibiotic treatment, before classifying them as viral infection without etiologic diagnosis.

Faringitis por Burkholderia cepacia. Transmisión de persona a persona / Pharyngitis due to Burkholderia cepacia. Person-to-person transmission

Burkholderia cepacia es un bacilo gramnegativo que se encuentra ampliamente distribuido en la naturaleza, y se aísla del suelo, el agua y las plantas y verduras. Generalmente produce infección nosocomial por contaminación de desinfectantes, equipos médicos, material protésico y fármacos, como anestésicos o líquidos de irrigación urológicos. El mecanismo de transmisión más probable es a través del material hospitalarios o de fomites entre personas tras un contacto de varias semanas o meses. Recientemente, se ha considerado como un patógeno importante en pacientes inmunodeprimidos o con enfermedades de base importantes, como la granulomatosis crónica y la fibrosis quística. Se presenta el caso de una faringitis por B. cepacia y su transmisión en pocos días en dos hermanos gemelos, inmunocompetentes y sin enfermedades de base previas y, la desaparición de la enfermedad tras la instauración de un tratamiento específico para este microorganismo. Consideramos que se deben tomar muestras de faringe y fosas nasales ante un proceso agudo del tracto respiratorio superior que no responde al tratamiento antibiótico empírico, antes de clasificarlo como viriasis sin diagnóstico etiológico (AU)